7 days ago
Indoco Remedies launches Ticagrelor tablets in UK through subsidiary
By Aditya Bhagchandani Published on June 3, 2025, 13:06 IST
Indoco Remedies Limited has officially launched its Ticagrelor film-coated tablets (90mg) in the United Kingdom through its subsidiary, Indoco Remedies UK Limited, on June 2, 2025. This marks a significant development for the company as it expands its international portfolio in the antiplatelet medication segment.
The newly launched product is aimed at reducing the risk of heart attacks, strokes, and other cardiovascular complications. It will be marketed and distributed across the UK by Clarity Pharma.
Commenting on the development, Aditi Kare Panandikar, Managing Director of Indoco Remedies, said, 'This development underscores our commitment to bringing high quality, life-saving treatments to patients in the UK.'
Indoco Remedies is a fully integrated pharmaceutical company with a global presence and a turnover of USD 180 million. The company has 11 manufacturing facilities and over 6,000 employees. It operates in various therapeutic segments, including gastrointestinal, respiratory, anti-infectives, and cardiovascular care, among others.
The UK launch of Ticagrelor further strengthens Indoco's footprint in the international market and reinforces its commitment to expanding its presence in regulated markets.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
